SHELLEY WALDMAN: Open Payments
NPI 1376971168 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$17,276 in 105 payments from 16 companies in 2025. Trend: 2023 $7,274 · 2024 $22,654 · 2025 $17,276
Speaker / faculty: $14,963Food & beverage: $2,300Travel & lodging: $13
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 50 | $8,762 |
| Janssen Biotech, Inc. | 18 | $7,649 |
| GENZYME CORPORATION | 6 | $157 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $135 |
| Lilly USA, LLC | 2 | $120 |
| Janssen Scientific Affairs, LLC | 1 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $82 |
| PFIZER INC. | 3 | $47 |
| Celltrion USA Inc. | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
Products named: TREMFYA, RINVOQ, SKYRIZI, STELARA, DUPIXENT, LINZESS, XIFAXAN, OMVOH.
Industry payments across KY — which companies pay providers there.
